Effect of magnesium supplementation in treatment of gestational diabetes

Clinical trial of the effect of magnesium supplementation compared with the placebo on gene expression related to inflammation and pregnancy outcomes in women with gestational diabetes mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N25

Enrollment

Registered

2017-12-29

Start date

2017-11-16

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: 250 mg magnesium (21st Century Pharmaceutical Company, Arizona, USA), daily for 6 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran)

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with gestational diabetes mellitus. Individuals aged 18 to 40 years.

Exclusion criteria

Exclusion criteria: Taking magnesium and antioxidants supplements 3 months before the intervention Needing insulin therapy Pre-eclampsia Eclampsia Hypo and hyperthyroidism Smokers

Design outcomes

Primary

Measure	Time frame
Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.

—

Secondary

Measure	Time frame
Expressed levels of TGF-B gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Newborn's head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Newborn's weight. Timepoint: Delivery time. Method of measurement: Scale.;Polyhydramnios. Timepoint: End-of-trial. Method of measurement: Sonography.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.	—

Measure

Time frame

Expressed levels of TGF-B gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Newborn's head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Newborn's weight. Timepoint: Delivery time. Method of measurement: Scale.;Polyhydramnios. Timepoint: End-of-trial. Method of measurement: Sonography.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026